Photo

Photo detail

Stories this photo appears in:

Halozyme Therapeutics Names LaBarre as Chief Scientific Officer

Halozyme Therapeutics Inc., a biotech developing novel oncology and drug-delivery therapies, named Michael J. LaBarre as chief scientific officer.

Tease photo

Halozyme Therapeutics Names Stelzer to Succeed Retiring CFO

Halozyme Therapeutics Inc., an oncology biotech in San Diego, reported that its chief financial officer, David Ramsay, will retire this summer.

Tease photo

Stelzer to Succeed Retiring CFO at Halozyme

Halozyme Therapeutics Inc., an oncology biotech in San Diego, reported that its chief financial officer, David Ramsay, will retire this summer.

Tease photo

FDA Approves Immunodeficiency Treatment From Halozyme Therapeutics And Baxter

San Diego-based Halozyme Therapeutics and Baxter International Inc. announced that the United States Food and Drug Administration approved Baxter’s subcutaneous treatment, HYQVIA, for adult patients with primary immunodeficiency.

Tease photo

Halozyme Drug Candidate Granted Fast Track Status

Halozyme Therapeutics Inc. announced that the Food and Drug Administration has granted Fast Track designation for its program investigating a treatment for patients with metastatic pancreatic cancer.

Tease photo

Halozyme Earns $5 Million Milestone Payment

San Diego-based Halozyme Therapeutics Inc. said the commercial launch of a cancer therapeutic in Europe has triggered a $5 million milestone payment to company under an agreement with Roche.

Tease photo

Halozyme Reports $26.5M Net Loss for First Quarter

Halozyme Therapeutics Inc. reported a net loss of $26.5 million, or 22 cents per share, on $12 million in revenue for the first quarter ended March 31. That compares with a net loss of $19.3 million — 17 cents per share — on revenue of $11.8 million for first quarter 2013.

Tease photo